A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma

Author： Li Ning   Ou Wei   Yang Hua   Liu Qian-Wen   Zhang Song-Liang   Wang Bao-Xiao   Wang Si-Yu  

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|120|9|1379-1386

ISSN： 0008-543X

Source： Cancer, Vol.120, Iss.9, 2014-05, pp. : 1379-1386

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Cost-effectiveness of Erlotinib versus Docetaxel for Second-line Treatment of Advanced Non-small-cell Lung Cancer in the United Kingdom

By Lewis G   Peake M   Aultman R   Gyldmark M   Morlotti L   Creeden J   de la Orden M  

The Journal of International Medical Research, Vol. 38, Iss. 1, 2010-01 ,pp. : 9-21

Field House Publishing

Access to resources Recommend Favorite

Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma

By Galsky Matthew   Mironov Svetlana   Iasonos Alexia   Scattergood Joseph   Boyle Mary   Bajorin Dean  

Investigational New Drugs, Vol. 25, Iss. 3, 2007-06 ,pp. : 265-270

Springer Publishing Company

Access to resources Recommend Favorite

A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma

By Hamid Omid   Ilaria Robert   Garbe Claus   Wolter Pascal   Maio Michele   Hutson Thomas E.   Arance Ana   Lorigan Paul   Lee Jeeyun   Hauschild Axel   Mohr Peter   Hahka-Kemppinen Marjo   Kaiser Christopher   Turner P. Kellie   Conti Ilaria   Grob Jean-Jacques  

Cancer, Vol. 120, Iss. 13, 2014-07 ,pp. : 2016-2024

Blackwell Publishing

Access to resources Recommend Favorite

The Role of EGFR Tyrosine Kinase Inhibitors in the First-Line Treatment of Advanced Non Small Cell Lung Cancer Patients Harboring EGFR Mutation

By  

Current Medicinal Chemistry, Vol. 19, Iss. 20, 2012-07 ,pp. : 3337-3352

Bentham Science Publishers

Access to resources Recommend Favorite

Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer

By Reckamp Karen L.   Koczywas Marianna   Cristea Mihaela C.   Dowell Jonathan E.   Wang He-Jing   Gardner Brian K.   Milne Ginger L.   Figlin Robert A.   Fishbein Michael C.   Elashoff Robert M.   Dubinett Steven M.  

Cancer, Vol. 121, Iss. 18, 2015-09 ,pp. : 3298-3306

Blackwell Publishing

Access to resources Recommend Favorite